- Hifas da Terra is proud to be part of the ai-vidda project, an initiative melting the Feder Galicia 2021-2027 Operational Programme, Which Focuses on Developing Advanced Solutions To Prevent Cognitive Decline In Older Adults Through The Integration of Artificial Intelligence and Biotechnolog.
- Hifas da Terra’s Role in This Groundbreaking Consortium Involves Biotechnological Research and the Development of Innovative Ingredients Derced Derced from Medicinal Mushroom Extracts, Specifying Targeting Cognitive Unpaid In Patients With Early Alzheimer’s Disease.
- The Ai-Vidda Project Boasts A Budget of € 3.6 Million and Will Involve 500 Patients, Making It The Largest Clinical Trial Ever Undertaken by Hifas da Terra.
Madrid, November 2024 -Hifas da Terra is at the Forefront of Biotechnological Research as part of the ai-vidda project (artificial Intelligence and Biotechnology Added to New Tools for Intervention in The Elderly to increase Healthy Lifespan). This Collaborative Initiative, Funded Through the Feder Galicia 2021-2027 Operational Programme, Aims to Revolutionise The Prevention and Treatment of Cognitive Unpaid in Older Adults by Developing Integrated Solutions Combining Artificial Intelligence and Biotechnology.
In Addition to Hifas da Terra, The Ai-Vidda Project Brings Together a Consortium of Organization Geriavi (Domusvi), Balidea Consulting & Programming, Trinidad Academia, Ni Nor NiCom 180, and Digital Invalabs. This Diverse Group of Experts in Health, Technology, and Education is United by The Goal of Fostering Active and Healthy Ageing. With an overall Budget of € 3.6 Million, € 1.65 Million of Which is co-Financed, The Project is part of the Smart Specialisation Missions of Galicia (RIS3 2021-2027). Notality, Only Two Projects were selected under This Funding Program, Underscoring the Competitive and Innovative Nature of Ai-Vidda.
The Project’s Primary Focus is The Creation of Advanced Tools to Promote Active and Healthy Ageing. By processing large volumes of data this artificial Intelligence, The Project Will Develop Personalized Intervention Strategies. Within This Framework, Hifas da Terra Will Lead The Biotechnological Research, Creating New Ingredients from Medicinal Mushroom Extracts Designed to Slow Cognitive Decline In Early-Stage Alzheimer’s Patients. This ambitious work Will culminate in the Most extensive clinical trial In Hifas da Terra’s History, Carried Out in Collaboration with the Biomedical Foundation Galicia Sur and INVOLVING 500 PATERS.
Hifas da Terra’s Participation in the Ai-Vidda Project reflects its dedication to biotechnological innovation and the pursuit of solutions that enhance the quality of life for Older Adults. This Initiative Represents A signan Milestone for the Company and Highlights The Untapped Potential of Medicinal Mushrooms in the Field of Applied Neuroscience.
Through Ai-Vidda, Hifas da Terra and its Consortium Partners Are Paving the Way for Groundbreaking Advancements in Tackling The Challenges of Ageing. This Project Further Establishments Galicia As a Leading Hub for Technological and Health Innovation.
References- 1st - García Hernández, Marisela, et al. "Immunomodulators as adjuvant therapy in infectious disease." University Medicine 11.45 (2009): 247-259.
- 2nd -damialis, Athanasios, et al. "Higher Airborne Pollen Concentrations correlated with increased Sars-Cov-2 Infection Rates, As evidenced from 31 Countries Across The Globe." Proceedings of the National Academy of Sciences 118.12 (2021).
- 3rd -Biedron, R., et al. "AGANICUS BLAZEI MURILL-IMMUNOMODULATORY PROPERTIES AND HEALTH BENEFITS." Functional Foods in Health and Disease 2.11 (2012): 428-447.
- 4th -Hetland G, Tangen JM, Mahmood F, et al. Antitumour, anti-inflammatory and antiallergic effects of agaricus blazei mushroom extract and the relatized medical re-lounges mushrooms, hericium erinaceus and tapolafrondosa: a Review of preclinical and clinical studies. Nutrients. 2020; 12 (5): 1339. Published 2020 May 8.
- 5th -Hetland G, Johnson E, Lyberg T, Kvalheim G. The Mushroom Agaricus Blazei Murill Medicinal Elicits Effects On Tumour, Infection, Allergy, and Inflammmation Through its Modulation of Innate Immundity and Amelioration of Th1/Th2 IMBALANCE AND INFLAMMATION. ADV Pharmacol Sci. 2011; 2011: 157015.
- 6th -ELLERTSEN LK, HETLAND G. AN EXTRACT OF THE MEDICINAL MUSHROOM AGANICUS BLAZEI MURILL CAN PROTECT AGAINST ALERGY. Clin Mol Allergy. 2009; 7: 6. Published 2009 May 5.
- 7th Mahmood F, Hetland G, Nentwich I, Mirlashari Mr, Ghiasvand R, Nissen-Meyer LSH. AGANICUS BLAZEI-BASED MUSHROOM EXTRACT SUPPLICATION TO BIRCH ALERGIC BLOOD DONORS: A RANDOMISED CLINICAL TRIAL. Nutrients. 2019 Oct 2; 11 (10): 2339.